Portal de Periódicos da CAPES

18F-Fluoromisonidazole in tumor hypoxia imaging

2017; Impact Journals LLC; Volume: 8; Issue: 55 Linguagem: Inglês

10.18632/oncotarget.21662

1949-2553

Zuoyu Xu, Xiaofeng Li, Hongyan Zou, Xilin Sun, Baozhong Shen,

Nanoplatforms for cancer theranostics

// Zuoyu Xu 1, 2 , Xiao-Feng Li 1, 2 , Hongyan Zou 1 , Xilin Sun 1, 2 and Baozhong Shen 1, 2 1 Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, China 2 TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China Correspondence to: Baozhong Shen, email: shenbz@ems.hrbmu.edu.cn Xilin Sun, email: sunxl@ems.hrbmu.edu.cn Keywords: hypoxia, 18 F-Fluoromisonidazole, PET, tumor Received: June 28, 2017 Accepted: September 21, 2017 Published: October 07, 2017 ABSTRACT Hypoxia is a common feature of solid tumors that is closely associated with radiotherapy and chemotherapy resistance, metastasis and tumors prognosis. Thus, it is important to assess hypoxia in tumors for estimating prognosis and selecting appropriate treatment procedures. 18 F-Fluoromisonidazole positron emission tomography ( 18 F-FMISO PET) has been widely used to visualize tumor hypoxia in a comprehensive and noninvasive way, both in the clinical and preclinical settings. Here we review the concept, mechanisms and detection methods of tumor hypoxia. Furthermore, we discuss the correlation between 18 F-FMISO PET and other detection methods, current applications of 18 F-FMISO PET and the development prospects of this imaging technology.